Ann Surg Treat Res.  2016 Dec;91(6):278-287. 10.4174/astr.2016.91.6.278.

Medullary thyroid carcinoma: a 30-year experience at one institution in Korea

• Lee CR
• Lee S
• Son H
• Ban E
• Kang SW
• Lee J
• Jeong JJ
• Nam KH
• Chung WY
• Park CS

• KMID: 2360387
• DOI: http://doi.org/10.4174/astr.2016.91.6.278

Abstract

PURPOSE
The objective of this study was to review the clinical outcome and prognosis of patients with sporadic and hereditary medullary thyroid cancer (MTC) who were treated at a single tertiary hospital in Korea.
METHODS
We retrospectively reviewed the case files of 85 patients treated from August 1982 to February 2012.
RESULTS
In all, 65 patients (76.5%) had sporadic MTC and 20 patients (23.5%) had hereditary MTC. Patients in the sporadic group were older than in the hereditary group (P < 0.001). However, the hereditary group had more tumor multiplicity (P < 0.001) and bilaterality (P < 0.001). Neither survival rate was significantly different between the sporadic and hereditary groups (P = 0.775 and P = 0.866). By multivariate analysis, distant metastasis was a significant prognostic factor for overall and progression-free survival.
CONCLUSION
In general, patients with MTC have favorable outcomes. Distant metastasis appears to be the strongest predictor of overall and progression-free survival.

Keyword

Familial medullary thyroid carcinoma; Prognosis; Survival

MeSH Terms

Disease-Free Survival
Humans
Korea*
Multivariate Analysis
Neoplasm Metastasis
Prognosis
Retrospective Studies
Survival Rate
Tertiary Care Centers
Thyroid Gland*
Thyroid Neoplasms*

Figure

• 

  Fig. 1 Overall survival rates in patients with medullary thyroid carcinoma (P = 0.775).

• 

  Fig. 2 Progression-free survival of patients with medullary thyroid carcinoma (P = 0.866).

• 

  Fig. 3 RET proto-oncogene genetic screening and counseling. *Patients underwent thyroid operation from January 1982 to February 2012.

Reference

1. Bachelot A, Lombardo F, Baudin E, Bidart JM, Schlumberger M. Inheritable forms of medullary thyroid carcinoma. Biochimie. 2002; 84:61–66.

2. Pacini F, Castagna MG, Cipri C, Schlumberger M. Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol). 2010; 22:475–485.

3. Farndon JR, Leight GS, Dilley WG, Baylin SB, Smallridge RC, Harrison TS, et al. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg. 1986; 73:278–281.

4. Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015; 25:567–610.

5. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000; 88:1139–1148.

6. Fromigue J, De Baere T, Baudin E, Dromain C, Leboulleux S, Schlumberger M. Chemoembolization for liver metastases from medullary thyroid carcinoma. J Clin Endocrinol Metab. 2006; 91:2496–2499.

7. Busnardo B, Girelli ME, Simioni N, Nacamulli D, Busetto E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer. 1984; 53:278–285.

8. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, et al. American Thyroid Association Guidelines Task Force. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009; 19:565–612.

9. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996; 276:1575–1579.

10. Mathew CG, Chin KS, Easton DF, Thorpe K, Carter C, Liou GI, et al. A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature. 1987; 328:527–528.

11. Heshmati HM, Gharib H, van Heerden JA, Sizemore GW. Advances and controversies in the diagnosis and management of medullary thyroid carcinoma. Am J Med. 1997; 103:60–69.

12. Gharib H, McConahey WM, Tiegs RD, Bergstralh EJ, Goellner JR, Grant CS, et al. Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970. Mayo Clin Proc. 1992; 67:934–940.

13. Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol (Oxf). 2004; 61:299–310.

14. Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid. 1996; 6:305–310.

15. Gülben K, Berberoglu U, Boyabatli M. Prognostic factors for sporadic medullary thyroid carcinoma. World J Surg. 2006; 30:84–90.

16. Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer. 1996; 77:1556–1565.

17. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'etude des tumeurs a calcitonine. Clin Endocrinol (Oxf). 1998; 48:265–273.

18. Grozinsky-Glasberg S, Benbassat CA, Tsvetov G, Feinmesser R, Peretz H, Shimon I, et al. Medullary thyroid cancer: a retrospective analysis of a cohort treated at a single tertiary care center between 1970 and 2005. Thyroid. 2007; 17:549–556.

19. Clark JR, Fridman TR, Odell MJ, Brierley J, Walfish PG, Freeman JL. Prognostic variables and calcitonin in medullary thyroid cancer. Laryngoscope. 2005; 115:1445–1450.

20. Kebebew E, Greenspan FS, Clark OH, Woeber KA, Grunwell J. Extent of disease and practice patterns for medullary thyroid cancer. J Am Coll Surg. 2005; 200:890–896.

21. Bergholm U, Bergstrom R, Ekbom A. Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer. 1997; 79:132–138.

22. Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS Jr, Hickey RC, et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore). 1984; 63:319–342.

23. Raue F, Kotzerke J, Reinwein D, Schröder S, Roher HD, Deckart H, et al. Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. Clin Investig. 1993; 71:7–12.

24. Figlioli G, Landi S, Romei C, Elisei R, Gemignani F. Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. Mutat Res. 2013; 752:36–44.

25. Bugalho MJ, Domingues R, Santos JR, Catarino AL, Sobrinho L. Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre. Surgery. 2007; 141:90–95.

26. Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab. 2007; 92:4725–4729.

27. Romei C, Elisei R, Pinchera A, Ceccherini I, Molinaro E, Mancusi F, et al. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab. 1996; 81:1619–1622.

28. Jhiang SM, Fithian L, Weghorst CM, Clark OH, Falko JM, O'Dorisio TM, et al. RET mutation screening in MEN2 patients and discovery of a novel mutation in a sporadic medullary thyroid carcinoma. Thyroid. 1996; 6:115–121.

29. Marsh DJ, Theodosopoulos G, Martin-Schulte K, Richardson AL, Philips J, Röher HD, et al. Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2003; 88:1866–1872.

30. Dvorakova S, Vaclavikova E, Sykorova V, Vcelak J, Novak Z, Duskova J, et al. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas. Mol Cell Endocrinol. 2008; 284:21–27.